treat systemic infections. PO-administered vancomycin however is widely utilized in people for localized treatment of Clostridium difficile enteric infections and prophylaxis. 3, 4 Acquisition of resistance mechanisms by bacterial organisms allows for amplification and propagation in human and animal populations. 5, 6 Pathogenic Staphylococcus is prevalent in a variety of companion animals, [7] [8] [9] and data show bidirectional transmission between companion animals and people, 9,10 indicating a clinically important zoonotic risk.
In people, vancomycin dosing is based on patient weight and creatinine clearance guided by daily therapeutic drug monitoring to avoid accumulation and toxicity. 11, 12 Potential adverse effects of vancomycin administration in people include nephrotoxicity, ototoxicity, neutropenia, and "red man syndrome," characterized by vasodilatation, flushing, and hypotension caused by histamine release from mast cells after rapid administration (>10 mg/min). 1, 13 Vancomycin-induced kidney injury in people is suspected to be caused by impurities in the vancomycin preparation or coadministration with other nephrotoxic drugs (such as aminoglycosides), because more recent reports have shown fewer cases of nephrotoxicity with vancomycin monotherapy. 2 The use of IV vancomycin in cats, 14, 15 pharmacokinetics in dogs, 16 and systemic use in horses 17 is reported in the veterinary literature, but clinical data documenting the parenteral use of vancomycin for naturally occurring infections are needed in small animal veterinary patients. Successful clinical outcomes in dogs with vancomycinsusceptible infections are limited to several case reports. [18] [19] [20] One case series reported 2 dogs that were inappropriately treated with PO vancomycin for severe soft tissue infections, highlighting the lack of familiarity and standardization of vancomycin administration in small animal practice. 21 Guidelines for prudent use of vancomycin to prevent vancomycin-resistant infections 22 as well as for appropriate treatment of MRSA organisms 23 are well established in people.
Several veterinary expert groups have published evidence-based recommendations for responsible use of antimicrobials 24, 25 including MRSA and MRSP infections, 25 and support is growing for restriction of glycopeptides such as vancomycin.
Our objective was to evaluate parenterally administered vancomycin in dogs and cats. The main aims were to describe the types of infections, clinical outcomes of patients and to report adverse events in patients treated with vancomycin.
| MATERIALS AND METHODS

| Data collection
Electronic medical records of the Foster Hospital for Small Animals at Tufts University were searched to identify all dogs and cats that were treated with vancomycin at any dosage or duration between January 2003 and October 2017. Patients were included in the study if vancomycin was administered and the medical record was available for review. To decrease selection bias, individual patients that were treated with vancomycin during >1 hospitalization were counted only once, with cumulative data reviewed in regard to duration of treatment and evidence of adverse effects.
The following variables were collected from the medical record: in the susceptibility data, it was noted whether de-escalation occurred (defined as discontinuation of vancomycin in ≤24 hours after culture and susceptibility data were finalized). Delayed de-escalation was defined as discontinuation of vancomycin in >24 hours after culture data were finalized. No de-escalation was defined as continued vancomycin administration after susceptibility data were finalized and until the time of discharge. 3 | RESULTS The suspected or confirmed source of primary infection is described in Table 2 . These data represent the infection for which the patient was originally hospitalized, not necessarily the infection for 
| Data analysis
| Population data
| Vancomycin data
The most commonly prescribed starting dosage of vancomycin was 15 mg/kg IV q6h (22/36 cases, 61.1%), but there was considerable variation (see Table 4 ). In 6 of 36 cases (16.7%), the initial starting dose or dosing frequency was altered at some point during the course of treat- Table 1 .
Overall patient adverse events detected are summarized in The sepsis category includes only cats and dogs that fulfilled sepsis criteria at the time of vancomycin initiation. Sepsis was defined as fulfillment of species-specific SIRS criteria and evidence of infection. Specific SIRS criteria for dogs included abnormal body temperature (<100.6 F or >102.6 F), tachycardia (HR > 120 bpm), tachypnea (>40 breaths/min), and abnormal leukogram (WBC count <6 × 10 3 /μL or >16 × 10 3 /μL or >3% bands). For cats, SIRS criteria were defined as abnormal body temperature (<100 F or >103.5 F), abnormal heart rate (HR < 140 bpm or >225 bpm), tachypnea (>40 breaths/ min), and abnormal leukogram (WBC count <5 × 10 3 /μL or >19.5 × 10 3 /μL or >5% bands).
pre-existing mild azotemia that did not progress with vancomycin treatment. Clear evidence of AKI was noted in 6 of 36 patients Organisms most frequently cultured from HAIs in our study were similar to those commonly treated with vancomycin in human patients, but cases in which vancomycin was the only appropriate option were rare (2/36, 1 of which was an HAI, 2.8% of all cases treated). In both of these cases, vancomycin was prescribed to treat enterococcal organisms that were part of a polymicrobial infection.
Enterococcal infections pose a unique treatment dilemma in that both
Enterococcus faecalis and Enterococcus faecium are important contributors to HAIs and are often highly resistant, but data in human medicine suggest that they do not always require treatment when detected as a coinfection with another organism and may resolve with antibiotics targeting the other components of mixed infection. 35 In addition, asymptomatic bacteriuria from multidrug resistant enterococcal colonization is common in hospitalized people who are catheterized and usually does not require treatment. 36 In contrast, resistant enterococcal species are important causes of serious infections such as endocarditis and meningitis in people and can contribute to substantial morbidity and mortality. Some evidence also exists that enterococcal infections are an important cause of postoperative abdominal infections in people. 37 Given the emergence of vancomycin resistance in people and the data presented in our study, it may be prudent to discourage vancomycin treatment for enterococcal infections when cultured as a coinfection. In addition, the susceptibility data reviewed here do not support empirical use of vancomycin for non-enterococcal infections, but it could be considered after full susceptibility data are available on a case-by-case basis.
In people, vancomycin-induced neutropenia, defined as absolute neutrophil counts <1000/μL, is reported in 2%-12% of treated patients and is related to duration of treatment (>7 days, with most cases occurring beyond day 20 of treatment), rather than daily doses, total cumulative doses, or incidence of supratherapeutic serum vancomycin concentrations. 38 No suspected cases of vancomycinassociated neutropenia were identified in our study, but most animals (18/36, 50.0%) were noted to either have pre-existing neutropenia or no documentation of a CBC performed after the start of treatment. In addition, only 6 animals were treated with vancomycin for ≥20 days.
Interestingly, 1 patient was treated continuously for >5 months after developing recurrent bacteremia after initial treatment was discontinued, but never developed neutropenia on subsequent CBCs.
Nephrotoxicity attributed to vancomycin use initially was seen when it was first isolated in the 1950s, but subsequent studies have
shown that newer formulations tested in the 1970s produced far less kidney damage, although the risk is greater with concurrent administration of aminoglycosides 39 or when administered in very high doses. 40 A recent meta-analysis in people has shown some evidence of the specific combination of vancomycin with piperacillintazobactam as having an association with higher rates of AKI when compared to vancomycin monotherapy, but specific prospective data are lacking. 41 The absolute risk of vancomycin-induced AKI is likely multifactorial and patient specific. The risk of vancomycin-induced nephrotoxicity may be higher in those that receive higher doses, longer duration of treatment, those concurrently treated with other drugs that have nephrotoxic potential, or in critically ill patients susceptible to poor renal perfusion. 42 In our study, 6 of 36 patients ( by the patient's creatinine clearance and adjusted by body weight and then titrated based on serum peak and trough vancomycin concentrations after the 4th dose, based on pharmacokinetic studies. 13, 43 In people, substantial evidence indicates that certain disease states such as sepsis or septic shock can alter serum drug concentrations. This is highly dependent on the patient's vascular permeability and subsequent alteration of volume of distribution and target organ concentration and organ dysfunction, which alters drug clearance. For hydrophilic antibiotics such as the glycopeptides, fluid shifts can cause increased volume of distribution, which leads to a decreased maximum serum drug concentration, whereas renal dysfunction tends to increase serum drug concentrations because of decreased clearance.
Because this is difficult to quantify at the bedside, therapeutic drug monitoring and dose adjustment (usually in conjunction with a clinical pharmacist) are required to avoid subtherapeutic dosing. 43, 44 This approach is recommended in a recent consensus statement by infectious disease specialists in human medicine. 44 Monitoring trough drug concentrations was found to be essential in avoiding vancomycin resistance from subtherapeutic dosing, but routine measurement of peak vancomycin concentrations could not be recommended because of conflicting evidence regarding the association of vancomycin blood levels and incidence of adverse effects. 44 To the best of our knowl- In conclusion, vancomycin administration in dogs and cats for lifethreatening infections was generally well tolerated, but additional prospective studies are needed to further evaluate the risk of AKI. Based on culture and susceptibility data in this specific population of dogs and cats, treatment with vancomycin rarely was necessary. Restriction of use to only patients with culture evidence of susceptibility that lack reasonable other antimicrobial options is warranted, which is in agreement with a recently published antimicrobial stewardship policy outlined by the American Veterinary Medical Association. 45 Further research regarding therapeutic drug monitoring to guide vancomycin treatment and its effects on prevention of antimicrobial resistance and adverse effects in veterinary species is warranted.
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